•Key technology of the multi-component solution is the VitalSky personalized light therapy system, now with CE Mark as a medical device
•VitalSky improves sleep quality in intensive care patients to help reduce delirium

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today introduced VitalMinds, an integrated multi-component solution focused on supporting hospitals with a non-pharmacological approach to reducing delirium. A unique, key component of the approach is VitalSky, a personalized light therapy system, designed for clinical use in the intensive care unit (ICU). The innovative system recently received CE Mark and is now commercially available in Germany, Austria, Switzerland, Finland and Sweden, with market launches planned in other European countries over the next two years.

Delirium challenge in Intensive Care Medicine
Delirium, a serious disturbance in mental abilities that results in confused thinking and reduced awareness of the environment, occurs in 30% to 80% of all ICU patients, making it the most common form of cognitive dysfunction in intensive care medicine [1]. The occurrence of this cerebral impairment during intensive care treatment has far-reaching consequences, doubling the mortality risk of patients in ICUs and even tripling mortality in the first six months following discharge from the hospital [1,2]. In view of these statistics, guidelines recommend systematic delirium screening for all patients in ICUs and the implementation of non-pharmacological interventions to prevent delirium, such as mobilizing patients during the day and introducing measures to promote sleep at night [3].







With VitalMinds, we have developed a new concept that combines light and sound management, circadian-effective light therapy, staff training and consulting services, to help hospitals reduce delirium and improve patient recovery in the ICU.
Felix Baader
Business Leader, Monitoring Analytics at Philips







“With VitalMinds, we have developed a new concept that combines light and sound management, circadian-effective light therapy, staff training and consulting services, to help hospitals reduce delirium and improve patient recovery in the ICU,” said Felix Baader, Business Leader, Monitoring Analytics at Philips. “This integrated approach is based on international ICU guidelines and supports hospitals in achieving the quadruple aim to improve patient and staff experience, deliver better health outcomes, and drive lower costs in intensive care medicine.”

VitalSky for Personalized Light Therapy
The VitalSky light therapy system provides a circadian-effective program to support the sleep-wake rhythm of patients. This program simulates the natural progression of daylight using a spectrum of glare-free white light provided by a large luminous LED ceiling. The light conditions can be personalized to the needs of the individual patient. The system also provides premium-quality workplace lighting to support favorable treatment conditions. Advanced features include the additional option of playing calming nature scenes in full-color, soft-focus video, and the future enablement of cognitive training is also planned. The various programs and settings can be selected and adjusted quickly and easily via a portable user interface.

“In the framework of a multi-component approach at Marien Hospital in Wesel, Germany, we aim to prevent delirium in the ICU. For this purpose, the light therapy technology of the VitalSky system is an essential environmental element which will help us to support the circadian rhythm of patients,” said Dr. Marc Achilles, Chief Physician of anesthesiology and intensive care medicine, Marien Hospital. “We are proud to be the first hospital worldwide where this system is installed.”

Improved Patient Environment Supports the Reduction of Delirium
Recent results from the VITALITY study of the Charité University Hospital in Berlin demonstrate the important role of an improved patient environment, including circadian-effective light therapy for the recovery process and the prevention of delirium in the ICU. The preliminary results of the VITALITY study show a statistically significant reduction of 39% in the incidence of delirium for patients treated in modified ICU rooms compared to patients treated in standard rooms [4].

More information on the VITALITY study results is available here. For further information on how Philips is supporting delirium prevention, visit VitalMinds.*

[1] Ouimet S. et al., Intensive Care Med, 2007, 33(1): 66-73
[2] Ely E.W. et al., JAMA, 2004, 291(14): 1753-62
[3] S3 guideline for the management of delirium, analgesia and sedation in intensive care medicine (DAS guideline 2015), http://www.awmf.org/leitlinien/detail/ll/001-012.html
[4] Luetz A. et al., Intensive Care Medicine Experimental, 2018, 6 (Suppl 2):40
*VitalMinds and VitalSky are not available for sale outside of the European market.

AND
Philips launches IntelliSpace Radiation Oncology to accelerate time from patient referral to the start of treatment.

Intelligent patient management solutions on display at ESTRO 2019 to complement latest radiotherapy imaging and treatment planning innovations

Amsterdam, the Netherlands and Milan, Italy – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced IntelliSpace Radiation Oncology [1], an intelligent patient management solution to manage complexity, improve efficiency and enable operational excellence in radiotherapy departments. IntelliSpace Radiation Oncology provides a harmonized way of working, integrating applications and automating workflow to help reduce the amount of time it takes from receiving a patient referral to the start of their treatment. The solution is being unveiled at the European Society for Radiation Oncology’s (ESTRO) 38th Annual Meeting in Milan, Italy on Friday April 26, 2019.

Radiotherapy is an important and cost-effective part of cancer treatment and control. More than half of all cancer types can be treated with radiotherapy [2], often in combination with other types of therapy such as surgery and chemotherapy. However, radiotherapy is often perceived as a complex treatment option due to the number of clinical specialists and advanced technologies required to deliver effective care. IntelliSpace Radiation Oncology is designed to manage this complexity by providing an integrated platform that connects all the steps from the patient’s referral to the start of their treatment.







By integrating all of the steps in the radiotherapy department’s workflow into one platform, IntelliSpace Radiation Oncology is designed to improve communication and harmonize ways of working across clinical teams, improving the consistency of care they provide.
Ardie Ermers
General Manager Radiation Oncology, Philips







“By integrating all of the steps in the radiotherapy department’s workflow into one platform, IntelliSpace Radiation Oncology is designed to improve communication and harmonize ways of working across clinical teams, improving the consistency of care they provide,” said Ardie Ermers, General Manager Radiation Oncology, Philips. “Each step of the patient’s journey is captured, providing a strong basis for automating workflows, enhancing efficiency and operational excellence.”

IntelliSpace Radiation Oncology is flexible and can be customized to the specific needs of a department and each clinician. It is an open, vendor-agnostic platform designed to provide comprehensive interoperability across the hospital IT environment.

To support healthcare providers in capitalizing on the insights and workflow improvement opportunities presented by the platform, Philips is also launching Radiation Oncology Practice Management [1]. This consultancy service will support radiotherapy departments in identifying and acting on data-driven insights to achieve operational excellence.

IntelliSpace Radiation Oncology is the latest addition to Philips’ renewed suite of radiation oncology systems and software. On show for the first time at ESTRO, the new portfolio includes Pinnacle Evolution treatment planning software, Big Bore RT, a dedicated oncology CT simulator, and the Ingenia Elition 3.0T MR-RT and Ambition 1.5T MR-RT systems.

At the show Philips also announced that it plans to expand its leading MR-only radiotherapy simulation portfolio with MRCAT brain [3]. Based on a single, fast MR scan and leveraging AI, Philips’ MRCAT brain will be designed to automatically generate CT-like density information on the MR console. Philips’ MR-only simulation technology, which also includes MRCAT pelvis and prostate, enables clinicians to rely on a single imaging modality by providing both MR’s superior soft-tissue contrast for delineation and density information for dose calculations.

Partnering for integrated imaging, planning and treatment
Philips’ strong partnerships across imaging, planning and treatment support increased precision and clinical confidence to help clinicians deliver the best possible care. In January 2019, Philips announced a collaboration with imaging solutions provider MIM Software Inc. (Cleveland, US), a company that provides practical imaging, automation, and data analysis solutions to radiation therapy clinics worldwide. Philips also has an ongoing collaboration with Sun Nuclear to integrate its suite of PlanIQ™ software into Pinnacle Evolution.

Philips’ collaboration with Elekta (Stockholm, Sweden), a leader in precision radiation medicine has resulted in the introduction of the Elekta Unity, the world's first high-field MR-linac (linear accelerator). Philips also has a long-standing partnership with IBA (Ion Beam Applications S.A, Louvain-La-Neuve, Belgium), a leading provider of proton beam therapy systems.

Visit Philips at booth #4000 at ESTRO 38. For more information about Philips’ presence at the show, including the full suite of Philips radiation oncology technology and integrated solutions, visit Philips’ ESTRO event website and follow @PhilipsLiveFrom for updates throughout #ESTRO38.

[1] IntelliSpace Radiation Oncology and Radiation Oncology Practice Management are considered works in progress and not available for sale.
[2] https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/basics.html.
[3] MRCAT brain is considered work in progress, is not CE marked and is not available for sale or distribution.